Neurocrine Biosciences | Actif À Court Terme



Current Assets Changement Date
AbbVie USD 25.58B 2.2B 2024-12
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
Agios Pharmaceuticals USD 965.6M 108.59M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Alnylam Pharmaceuticals USD 3.3B 60.14M 2024-12
Amgen USD 29.03B 2.26B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Cytokinetics USD 1.11B 89.34M 2024-12
Dynavax Technologies USD 848.94M 77.3M 2024-12
Exelixis USD 1.47B 82.14M 2025-01
Gilead Sciences USD 19.17B 4.39B 2024-12
Halozyme Therapeutics USD 1.09B 41.64M 2024-12
Incyte USD 3.23B 7.24M 2025-03
Ionis Pharmaceuticals USD 2.42B 201.36M 2025-03
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Pfizer USD 50.36B 7.14B 2024-12
Prothena USD 485.41M 49.57M 2024-12
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Repligen USD 1.03B 33.58M 2025-03
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
Teva Pharmaceutical Industries USD 12.55B 238M 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Neurocrine Biosciences Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.